{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:35:23Z","timestamp":1789263323987,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Psoriasis is a chronic inflammatory disease that frequently affects difficult-to-treat areas such as the scalp, nails, genitalia, and palms\/soles, with significant physical and psychological burden. Bimekizumab, a monoclonal antibody targeting both interleukin (IL)-17A and IL-17F, has shown rapid and durable efficacy in clinical trials, but real-world data in these subgroups remain limited. Methods: We performed a 52-week, single-center retrospective study including patients with psoriasis involving at least one difficult-to-treat area. Effectiveness was assessed using site-specific Physician\u2019s Global Assessment (sc-PGA, f-PGA, sPGA-G, pp-PGA). The primary endpoint was the proportion of patients achieving a PGA 0\/1 (clear or almost clear). Safety data were collected at each visit. Results: Eighty-five patients were included (61.8% male; mean age 48.1 years; mean Body Mass Index (BMI, 26.9 kg\/m2). Difficult-to-treat areas involved were the scalp (70.6%), nails (41.2%), genitalia (27.1%), and palms\/soles (24.7%). At week 52, sc-PGA 0\/1 was achieved in 90.6% of patients, sPGA-G 0\/1 in 81.3%, f-PGA 0\/1 in 66.7%, and pp-PGA 0\/1 in 87.5%. Mean PGA values progressively decreased across all sites. The most common adverse event was oral candidiasis (11.8%). Conclusions: Bimekizumab showed rapid, sustained, and clinically meaningful improvement across all difficult-to-treat areas with a favorable safety profile.<\/jats:p>","DOI":"10.3390\/jcm14207412","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:54:41Z","timestamp":1760968481000},"page":"7412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-Life Effectiveness and Safety of Bimekizumab in Plaque Psoriasis Involving Difficult-to-Treat Areas: A 52-Week, Retrospective Real-World, Single-Center Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9859-4475","authenticated-orcid":false,"given":"Matteo","family":"Bianco","sequence":"first","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioele","family":"Ghezzi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3780-5318","authenticated-orcid":false,"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8581","authenticated-orcid":false,"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/09546634.2020.1770175","article-title":"Psoriasis in difficult to treat areas: Treatment role in improving health-related quality of life and perception of the disease stigma","volume":"33","author":"Lanna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2023245","DOI":"10.5826\/dpc.1303a245","article-title":"Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review","volume":"13","author":"Cannizzaro","year":"2023","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clindermatol.2007.10.026","article-title":"Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas","volume":"26","author":"Wozel","year":"2008","journal-title":"Clin. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","article-title":"Combining biologic therapies with other systemic treatments in psoriasis: Evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation","volume":"151","author":"Armstrong","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14656566.2018.1448788","article-title":"Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas","volume":"19","author":"Kivelevitch","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2220849","DOI":"10.1080\/09546634.2023.2220849","article-title":"Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: A real-world experience from two referral centers","volume":"34","author":"Orsini","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110352","DOI":"10.1016\/j.clim.2024.110352","article-title":"IL-17 in skin infections and homeostasis","volume":"267","year":"2024","journal-title":"Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Brembilla, N.C., and Boehncke, W.H. (2023). Revisiting the interleukin 17 family of cytokines in psoriasis: Pathogenesis and potential targets for innovative therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1186455"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/1744666X.2016.1112739","article-title":"Interleukin 17-A inhibition in the treatment of psoriasis","volume":"12","author":"Yiu","year":"2016","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kokolakis, G., and Ghoreschi, K. (2022). The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010035"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2025.04.038","article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial","volume":"93","author":"Blauvelt","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3\/3b Randomized Controlled Trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: Pooled data from up to 3 years of treatment in randomized phase III trials","volume":"190","author":"Gordon","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","volume":"89","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/bjd\/ljac021","article-title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: Longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial","volume":"188","author":"Vender","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, G., and Campanati, A. (2023). Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: A real-life multicenter study-IL PSO (Italian landscape psoriasis). Front. Med., 10.","DOI":"10.3389\/fmed.2023.1243843"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Campione, E., Artosi, F., Shumak, R.G., Giunta, A., Argenziano, G., Assorgi, C., Balato, A., Bernardini, N., Brunasso, A.M.G., and Burlando, M. (2024). Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101378"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","article-title":"Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience\u2014IL PSO (Italian Landscape Psoriasis)","volume":"14","author":"Orsini","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_29","first-page":"e297","article-title":"Bimekizumab for the treatment of genital, scalp, and nail psoriasis: A 52-week real-world study","volume":"52","author":"Hagino","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","article-title":"Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)","volume":"14","author":"Valenti","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/ced\/llae400","article-title":"The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: A 16-week multicentre real-world experience\u2014IL PSO (Italian Landscape Psoriasis)","volume":"50","author":"Megna","year":"2025","journal-title":"Clin. Exp. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:18:33Z","timestamp":1760969913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":31,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207412"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207412","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}